OptiBiotix Health PLC Extension of terms for WellBiome with Agropur (8032T)
July 23 2020 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8032T
OptiBiotix Health PLC
23 July 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Extension of terms for WellBiome(R) with Agropur MSI, LLC
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has
extended the terms of its original manufacturing, supply and profit
sharing agreement with Agropur MSI, LLC ("Agropur") as announced on
24 June 2019.
The agreement builds on the commercial launch of SlimBiome(R) to
the North Amercian market as announced on 31 January 2020 and first
deliveries to customers in the territory as announced on 4 May
2020. It extends the product range from the manufacturing and
distribution of SlimBiome(R) to include WellBiome(R). The
territories remain unchanged with manufacturing and distribution
rights in the USA, Canada and Mexico.
WellBiome(R) is a proprietary blend of prebiotic functional
fibres, functional dietary fibres and mineral optimised for health
and wellbeing by promoting the diversity of the gut microbiome. The
functional ingredient was launched at the end of June 2020 (RNS: 29
June 2020) in response to commercial partners expressing strong
interest for an ingredient that would expand the commercial
opportunity beyond slimming and provide a solution
to the Health & Wellness industry , a market estimated to be worth US$4.2 trillion in 2019.
Mike Homewood, Vice-President of Customs Solutions at Agropur,
commented: "We are happy to have OptiBiotix once again show their
confidence in Agropur to manufacture and market another impressive
and innovative gut health product to health and wellness brands
across North America."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: " We are pleased to announce the extension
of terms for Agropur . This agreement recognises Agropur's success
in building sales of SlimBiome(R) with first deliveries in the
territory in Q2 2020 through Smart for Life, Inc. as announced on 4
May 2020. The agreement extends terms to support further sales
growth and is a third commercial step (RNS: 6 July 2020 and 14 July
2020) in bringing our new functional ingredient WellBiome(R) to
global markets and building brand awareness. This is an important
agreement as it will help OptiBiotix access a wider range of
customers in North America, a market where the understanding of the
microbiome is gaining momentum."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKKBBBPBKDDOB
(END) Dow Jones Newswires
July 23, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024